IP Library Granted Patent US 10,538,560
Granted Patent B2
US 10,538,560 · App. 16/115,303 · Granted Jan 21, 2020

Opsin polypeptides and methods of use thereof

Inventors: Karl Deisseroth (Stanford, CA); Feng Zhang (Cambridge, MA); Viviana Gradinaru (Pasadena, CA)
Assignee: The Board of Trustees of the Leland Stanford Junior University
C07K14/47A61N5/06C07K14/415C12N13/00A61K38/00A61K48/00A61K48/005C07K2319/03C07K2319/04C07K2319/60
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,538,560
App. No.
16/115,303
Granted
Jan 21, 2020
Kind
B2
Abstract

The present disclosure provides opsins, including variant opsins with increased activity and/or increased trafficking to the plasma membrane. The opsins are useful in therapeutic and screening applications, which are also provided.

Claims (24)

1. An isolated polynucleotide comprising a nucleotide sequence encoding a fusion polypeptide comprising, in order from amino terminus to carboxyl terminus:

a) an opsin polypeptide comprising an amino acid sequence having at least 90% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO:33;

b) a membrane trafficking signal comprising the amino acid sequence KSRITSEGEYIPLDQIDINV (SEQ ID NO: 10); and

c) an endoplasmic reticulum (ER) export signal comprising the amino acid sequence FXYENE (SEQ ID NO: 4), where X is any amino acid.

2. The polynucleotide of claim 1 , wherein the nucleotide sequence is operably linked to a promoter that provides for neuron-selective expression.

3. The polynucleotide of claim 1 , wherein the nucleotide sequence is codon optimized for expression in a mammalian cell.

4. The polynucleotide of claim 1 , wherein the ER export signal comprises the amino acid sequence FCYENE (SEQ ID NO:5).

5. A recombinant expression vector comprising the isolated polynucleotide of claim 1 .

6. The recombinant expression vector of claim 5 , wherein the recombinant vector is a lentiviral vector, an adenoviral vector, or an adeno-associated viral vector.

7. A mammalian cell comprising a light-activated fusion polypeptide expressed on the cell membrane, wherein the light-activated fusion polypeptide is capable of mediating a hyperpolarizing current in the cell when the cell is illuminated with light, and wherein the light-activated fusion polypeptide comprises, in order from amino terminus to carboxyl terminus:

a) an opsin polypeptide comprising an amino acid sequence having at least 90% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO:33;

b) a membrane trafficking signal comprising the amino acid sequence KSRITSEGEYIPLDQIDINV (SEQ ID NO: 10); and

c) an endoplasmic reticulum (ER) export signal comprising the amino acid sequence FXYENE (SEQ ID NO: 4), where X is any amino acid.

8. The mammalian cell of claim 7 , wherein the cell is a neuronal cell.

9. A method of modulating the voltage potential of a cell in response to a light stimulus, the method comprising exposing a cell to a light stimulus, wherein the cell that is genetically modified with a recombinant expression vector comprising a nucleotide sequence encoding a fusion polypeptide, wherein the fusion polypeptide comprises, in order from amino terminus to carboxyl terminus:

i) an opsin polypeptide comprising an amino acid sequence having at least 90% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO:33;

ii) a membrane trafficking signal comprising the amino acid sequence KSRITSEGEYIPLDQIDINV (SEQ ID NO: 10); and

ii) an endoplasmic reticulum (ER) export signal comprising the amino acid sequence FXYENE (SEQ ID NO: 4), where X is any amino acid,

wherein the encoded fusion polypeptide is expressed in the cell, and wherein, in response to exposure to a light stimulus, the voltage potential of the cell is modulated.

10. The method of claim 9 , wherein the cell is a neuronal cell.

11. The method of claim 9 , wherein the cell is in vitro.

12. The method of claim 9 , wherein the cell is in vivo.

13. The method of claim 9 , wherein the light stimulus is provided by an implantable light source.

14. The method of claim 9 , wherein the light stimulus is provided by a light-emitting diode.

Assignments (2)
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNOR NAME PREVIOUSLY RECORDED AT REEL: 047933 FRAME: 0970. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jan 23, 2019
From: DEISSEROTH, KARL A.; ZHANG, FENG; GRADINARU, VIVIANA
To: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Reel/Frame 048116/0575 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 8, 2019
From: DEISSEROTH, KARL A.; ZHANG, FANG; GRADINARU, VIVIANA
To: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Reel/Frame 047933/0970 →
Continuity (7)
Division 15962773 · Apr 25, 2018
Division 15799881 · Oct 31, 2017
Division 15334007 · Oct 25, 2016
Division 15097925 · Apr 13, 2016
Division 14365477
Provisional Application 61576858 · Dec 16, 2011
Related Publication 20190071476A1 · Mar 7, 2019